CN1480173A - Chinese herbal medicine for treating gynecology disease and its preparing method - Google Patents
Chinese herbal medicine for treating gynecology disease and its preparing method Download PDFInfo
- Publication number
- CN1480173A CN1480173A CNA021398054A CN02139805A CN1480173A CN 1480173 A CN1480173 A CN 1480173A CN A021398054 A CNA021398054 A CN A021398054A CN 02139805 A CN02139805 A CN 02139805A CN 1480173 A CN1480173 A CN 1480173A
- Authority
- CN
- China
- Prior art keywords
- radix
- radix angelicae
- medicine
- angelicae sinensis
- atractylodis macrocephalae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 title description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title description 4
- 238000000034 method Methods 0.000 title description 3
- 241000411851 herbal medicine Species 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 22
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 18
- 239000000843 powder Substances 0.000 claims description 18
- 108010052008 colla corii asini Proteins 0.000 claims description 14
- 229940056582 human hair preparation Drugs 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 8
- 238000005325 percolation Methods 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000001035 drying Methods 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000009495 sugar coating Methods 0.000 claims description 4
- 235000019640 taste Nutrition 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 9
- 239000000463 material Substances 0.000 abstract description 4
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 241000405414 Rehmannia Species 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 238000012360 testing method Methods 0.000 description 7
- PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 210000002784 stomach Anatomy 0.000 description 5
- 210000004291 uterus Anatomy 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 206010027514 Metrorrhagia Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000023597 hemostasis Effects 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 208000002173 dizziness Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005242 forging Methods 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 208000013433 lightheadedness Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- RODXRVNMMDRFIK-UHFFFAOYSA-N scopoletin Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(O)=C2 RODXRVNMMDRFIK-UHFFFAOYSA-N 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 1
- FZRCKLPSHGTOAU-UHFFFAOYSA-N 6-amino-1,4-dimethylcyclohexa-2,4-diene-1-carbaldehyde Chemical compound CC1=CC(N)C(C)(C=O)C=C1 FZRCKLPSHGTOAU-UHFFFAOYSA-N 0.000 description 1
- 206010061623 Adverse drug reaction Diseases 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- XEHFSYYAGCUKEN-UHFFFAOYSA-N Dihydroscopoletin Natural products C1CC(=O)OC2=C1C=C(OC)C(O)=C2 XEHFSYYAGCUKEN-UHFFFAOYSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- IBPFZCOJYVDKGN-UHFFFAOYSA-N OC.OC=O.ClC(Cl)Cl.CCOC(C)=O Chemical compound OC.OC=O.ClC(Cl)Cl.CCOC(C)=O IBPFZCOJYVDKGN-UHFFFAOYSA-N 0.000 description 1
- YKRGDOXKVOZESV-WRJNSLSBSA-N Paeoniflorin Chemical compound C([C@]12[C@H]3O[C@]4(O)C[C@](O3)([C@]1(C[C@@H]42)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)C)OC(=O)C1=CC=CC=C1 YKRGDOXKVOZESV-WRJNSLSBSA-N 0.000 description 1
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 1
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041954 Starvation Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000036029 Uterine contractions during pregnancy Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000003760 hair shine Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 235000021395 porridge Nutrition 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- FWYIBGHGBOVPNL-UHFFFAOYSA-N scopoletin Natural products COC=1C=C2C=CC(OC2=C(C1)O)=O FWYIBGHGBOVPNL-UHFFFAOYSA-N 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000021419 vinegar Nutrition 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 239000009306 yunnan baiyao Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A Chinese medicine for treating gynopathy is prepared from 12 Chinese-medicinal materials including Chinese angelica root, prepared rehmannia root, white peony root, yam, etc. Its advantage is high curative effect (90.3% for total effective rate).
Description
Technical field:
The present invention relates to a kind of medicine for the treatment of gynaecopathia, specifically relating to a kind of is medicine of making of raw material and preparation method thereof with Chinese medicine
Background technology:
Dysfunctional uterine bleeding is a kind of commonly encountered diseases, frequently-occurring disease, and the Therapeutic Method of modern medicine mainly is the hormonotherapy and the clearing heat in the pericardium, these Therapeutic Method, and it is big to exist drug side effect, easily recurrence, the deficiency of late result difference.
Summary of the invention:
The object of the present invention is to provide a kind of spleen invigorating of enriching blood, solid that has through the leukorrhagia stopping effect, to the good effect of gynaecopathia, a kind of Chinese medicine for the treatment of gynaecopathia that has no side effect and preparation method thereof.
Medicine of the present invention is the medicament of being made by following raw material and percentage by weight: Radix Angelicae Sinensis 6-12, Radix Rehmanniae Preparata 6-12, Radix Dipsaci 6-12, Radix Paeoniae Alba 6-12, Rhizoma Dioscoreae 6-12, Rhizoma Atractylodis Macrocephalae 6-12, Radix Sanguisorbae 6-12, Radix Angelicae Dahuricae 6-12, Concha Ostreae 6-12, Endoconcha Sepiae 6-12, Colla Corii Asini 6-12, Crinis Carbonisatus 4-7.
Preferred proportioning is: Radix Angelicae Sinensis 7.5-9.5, Radix Rehmanniae Preparata 7.5-9.5, Radix Dipsaci 7.5-9.5, Radix Paeoniae Alba 7.5-9.5, Rhizoma Dioscoreae 7.5-9.5,, Rhizoma Atractylodis Macrocephalae 7.5-9.5, Radix Sanguisorbae 7.5-9.5, Radix Angelicae Dahuricae 7.5-9.5, Concha Ostreae 7.5-9.5, Endoconcha Sepiae 7.5-9.5, Colla Corii Asini 7.5-9.5, Crinis Carbonisatus 5.0-6.5.
Technical scheme of the present invention is based on traditional Chinese medicine and learns pathogenetic understanding of gynaecopathia and Therapeutic Principle, screens from motherland's medicine treasure-house.
Prescription meaning analysis of the present invention: motherland's medical science is thought, CHONG meridian being the blood pool, and the blood lineage is in spleen, and is hidden in liver.Insufficiency of the spleenly can not take the photograph blood, deficiency of the liver can not store blood, so that chong channel is solid, so metrostaxis; Spleen insufficiency, water disappears wet can not the branch, and turbid damp is made a bet, so see leukorrhagia; Dash to appoint then abdomen dull pain less of inanition through the back; Light-headedness, lusterless complexion are levying of blood deficiency.Radix Angelicae Sinensis, enriching blood is monarch drug.Colla Corii Asini, Radix Rehmanniae Preparata, the Radix Paeoniae Alba, Radix Dipsaci invigorating the liver and kidney, benefiting essence-blood; Rhizoma Dioscoreae, Rhizoma Atractylodis Macrocephalae strengthening the spleen and stomach, Yi Huayuan is ministerial drug altogether.Radix Sanguisorbae, Concha Ostreae, Endoconcha Sepiae, Crinis Carbonisatus hemostasis leukorrhagia stopping; Radix Angelicae Dahuricae dampness leukorrhagia stopping is adjuvant drug.Full side mutually 5 gathers the spleen invigorating of enriching blood altogether, Gu through the merit of leukorrhagia stopping.
Modern pharmacological research shows that above medicine has following pharmacological action:
Radix Angelicae Sinensis: contain two kinds of compositions excited and the inhibition uterine smooth muscle, the excited uterus of Radix Angelicae Sinensis water soluble ingredient energy, uterine contraction is strengthened, its volatile oil then suppresses uterus muscle, make atony of uterus, have " amphicheirality " effect, can regulate the uterus smooth muscle contraction, remove spasm and reach the menstruction regulating and pain relieving effect; Radix Angelicae Sinensis is irritated the water-leach liquor that stomach is made when the volatile oil of going back to the acute mice that causes blood deficiency after losing blood greatly, hemoglobin and erythrocyte value is all had obviously increase, and illustrate that Radix Angelicae Sinensis has hematosis extremely significantly.
Radix Rehmanniae: water decoction or pure preserved material lumbar injection, can shorten the mouse tail bleeding time; Can promote the reparation of blood deficiency animal RBC, Hb, accelerate myeloid element CFU-S, the increment of CF-E, differentiation, have significant hematosis.
The Radix Paeoniae Alba: the Radix Paeoniae Alba total glucosides intramuscular injection is in mice, be dosage according to patience suppress mouse writhing, tear cry, the hot plate reaction, and can strengthen morphine respectively, clonidine suppresses the mouse writhing reaction, the prompting Radix Paeoniae Alba total glucosides has analgesic activity.
Rhizoma Dioscoreae: it is insufficiency of the spleen that Rhizoma Dioscoreae medicated porridge can prevent to gavage the rat experiment that vinegar causes, and Rats with Spleen-deficiency is had certain therapeutical effect.
The Rhizoma Atractylodis Macrocephalae: decoct is irritated stomach January, can promote the mice weight increase and strengthen swimming endurance, matches with the Rhizoma Atractylodis Macrocephalae " strengthening the spleen and stomach, strong health " of ancient literature record.
Radix Sanguisorbae: intraperitoneal administration can obviously shorten the animal bleeding time, and anastalsis is arranged.
The Radix Angelicae Dahuricae: the Radix Angelicae Dahuricae and plurality of active ingredients thereof have spasmolysis at body or isolated rat hysterospasm to scopoletin due to estrogen or barium chloride.
Colla Corii Asini: to the dog that RBC and Hb are descended, the growth rate of its RBC, Hb is accelerated, be shown that Colla Corii Asini has powerful blood tonification effect.
Crinis Carbonisatus: its extracting solution can obviously shorten the large and small Mus bleeding time, has anastalsis.
The dysfunctional uterine bleeding that clinical employing Drug therapy blood-deficiency and spleen-weakness of the present invention causes (belong to the traditional Chinese medical science metrorrhagia scope) 62 examples, Therapeutic Method are oral 3 times of every days, and each 6, every contains 0.3 gram.
Therapeutic outcome is as follows: according to stop blooding the in the recent period evaluation of standard of the whole nation, treat hemostasis in 7 days, observing 7 days no bleeders be produce effects, hemostasis in 8-10 days, and it is effective observing 7 days no bleeders, treats that to stop blooding in 10 days be invalid.This organizes produce effects 45 examples in 62 examples as a result, accounts for 72.6%, and effective 11 examples account for 17.7%, and invalid 6 examples account for 9.7%, and total effective rate is 90.3%.To blood-deficiency and spleen-weakness, leukorrhagia matter is clear, and the metrorrhagia color is light, through after lack abdomen dull pain, Light-headedness, diseases such as lusterless complexion all have satisfied curative effect.
Pharmacodynamic study shows that this product and YUNNAN BAIYAO relatively can obviously promote animal thrombosis, improves platelet adhesion ability (P＜0.05); Compare with chalybeate, can accelerate the growth rate (P＜0.05) of Hb H b, erythrocyte RBC; Mouse stomach can promote its weight increase; Behind the rat oral administration, in the body uterus tangible contraction being arranged, its shrinkage amplitude is similar substantially to the intramuscular injection pituitrin.Above-mentioned pharmacodynamic experiment research is the spleen invigorating of enriching blood of this product, and hemostasis is solid through abundant foundation is provided.
Acute toxicity testing shows the maximum this product toxicity little (LD50 can not survey) of limiting the quantity of; Long term toxicity test adopts 25,75 times of administrations of the suitable clinical dosage of rat three months, and every index there is no obvious adverse reaction, shows under clinical recommended dose it is safe.Take through patients clinical and not see untoward reaction in 30 days.
The preparation method of its tablet may further comprise the steps:
(1) Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Rhizoma Dioscoreae half and half amount and Crinis carbonisatus powder are broken into fine powder, sieving for standby;
(2) Radix Angelicae Sinensis, Radix Angelicae Dahuricae pulverize separately become coarse powder, and wherein Radix Angelicae Sinensis is made solvent with 5～6 times of amount 70% ethanol, and the Radix Angelicae Dahuricae is made solvent with 5～6 times of amount 60% ethanol, and percolation carries out percolation, collects the liquid of filtering, makes extractum routinely respectively
(3) five tastes such as all the other Radix Rehmanniae Preparata and the remaining Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Rhizoma Dioscoreae decoct with water secondary, and 3 hours for the first time, 2 hours for the second time, collecting decoction filtered, and filtrate is concentrated into relative density and is about 1.28 thick paste;
(4) go into after Colla Corii Asini dissolves, add above-mentioned powder again, mixing, drying is ground into fine powder;
(5) add Radix Angelicae Sinensis, Radix Angelicae Dahuricae extractum, mixing is granulated, and is pressed into the sheet of 0.3g, and sugar coating promptly.
The specific embodiment:
Embodiment 1:
(1) get Radix Paeoniae Alba 48.75kg, Rhizoma Atractylodis Macrocephalae 48.75kg, Rhizoma Dioscoreae 48.75kg, Crinis Carbonisatus 65kg is ground into fine powder, sieves.
(2) get Radix Angelicae Sinensis 97.5kg, Radix Angelicae Dahuricae 97.5kg pulverize separately becomes coarse powder, according to the percolation under fluid extract and the extractum item (appendix IO of Chinese Pharmacopoeia), Radix Angelicae Sinensis is made solvent with 5～6 times of amount 70% ethanol, and the Radix Angelicae Dahuricae is made solvent with 5～6 times of amount 60% ethanol, carries out percolation respectively, the collection liquid of filtering, make extractum respectively, get eumenol 38.2kg, Radix Angelicae Dahuricae extractum 33.8kg.
(3) get Radix Rehmanniae Preparata 98kg, Radix Dipsaci 97.5kg, Radix Sanguisorbae 97.5kg, Concha Ostreae 97.5kg, Endoconcha Sepiae 97.5kg and Radix Paeoniae Alba 48.75kg, Rhizoma Atractylodis Macrocephalae 48.75kg, Rhizoma Dioscoreae 48.75kg puts and extracts twice in the extraction pot, adds water 3800kg (about 6 times) at every turn, 3 hours for the first time, 2 hours for the second time, the united extraction medicinal liquid filtered, filtrate is concentrated into the thick paste of relative density about 1.28, gets thick paste 74.3kg, after adding Colla Corii Asini 97.5kg dissolves, add above-mentioned (1) powder again, mixing, drying is ground into fine powder, add (2) Radix Angelicae Sinensis, Radix Angelicae Dahuricae extractum, mixing is granulated, and is pressed into the sheet of 0.3g, sugar coating, promptly.
Embodiment 2:
[prescription] Radix Angelicae Sinensis 90g Radix Rehmanniae Preparata 90g Radix Dipsaci 60g Radix Paeoniae Alba 60g
Rhizoma Dioscoreae 60g Rhizoma Atractylodis Macrocephalae 60g Radix Sanguisorbae (stir-fry) 60g Radix Angelicae Dahuricae 60g
Concha Ostreae (forging) 90g Endoconcha Sepiae 90g Colla Corii Asini (medicinal glue) 90g
Crinis Carbonisatus 50g
[method for making] above 12 flavors, except that Colla Corii Asini, the Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Rhizoma Dioscoreae half and half amount and Crinis carbonisatus powder are broken into fine powder, sieve; Radix Angelicae Sinensis, Radix Angelicae Dahuricae pulverize separately become coarse powder, and according to the percolation (2000 editions one appendix 1 O of Chinese Pharmacopoeia) under fluid extract and the extractum item, Radix Angelicae Sinensis is made solvent with 5～6 times of amount 70% ethanol, the Radix Angelicae Dahuricae is made solvent with 5～6 times of amount 60% ethanol, carry out percolation respectively, collect the liquid of filtering, make extractum respectively; The five tastes such as all the other Radix Rehmanniae Preparata and the remaining Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Rhizoma Dioscoreae decoct with water secondary, and 3 hours for the first time, 2 hours for the second time, collecting decoction, filter, filtrate is concentrated into relative density and is about 1.28 thick paste, after the adding Colla Corii Asini dissolves, add above-mentioned powder again, mixing is granulated, and is pressed into 1000, sugar coating, promptly.
Embodiment 3:
[prescription] Radix Angelicae Sinensis 60g Radix Rehmanniae Preparata 60g Radix Dipsaci 90g Radix Paeoniae Alba 90g
Rhizoma Dioscoreae 90g Rhizoma Atractylodis Macrocephalae 90g Radix Sanguisorbae (stir-fry) 90g Radix Angelicae Dahuricae 90g
Concha Ostreae (forging) 60g Endoconcha Sepiae 60g Colla Corii Asini (medicinal glue) 60g
Crinis Carbonisatus 50g.
Method by embodiment 2 is made finished product.
[character]: this product is a coated tablet, removes to show brownish black behind the sugar-coat; Feeble QI is smelly, bitter in the mouth.
[discriminating]:
(1) get 2 of this product, remove sugar-coat, porphyrize adds water 10ml, puts in the water-bath and heats 5 minutes, filters, and gets filtrate 1ml, adds ninhydrin solution 0.5ml, puts in the water-bath and heats, the solution displaing amaranth.
(2) get 10 of this product, remove sugar-coat, porphyrize is put in the flask, adds solene (60～90 ℃) 30ml, puts in the water-bath and refluxes 40 minutes, filters, and filtrate is concentrated into 1ml, as need testing solution.Other gets Rhizoma Atractylodis Macrocephalae control medicinal material 1g, shines medical material solution in pairs with legal system.Test according to thin layer chromatography (2000 editions appendix VIB of Chinese Pharmacopoeia), draw each 5 μ l of above-mentioned two kinds of freshly prepd solution, put respectively on same silica gel g thin-layer plate, with petroleum ether (60～90 ℃)-ethyl acetate (100: 2) is developing solvent, launch, take out, dry, spray is with 10% sulfuric acid solution of 5% paradime thylaminobenzaldehyde, and it is clear that hot blast blows to the speckle colour developing.In the test sample chromatograph, with the corresponding position of control medicinal material chromatograph on, show the speckle of same color.
(3) get the residue behind the Petroleum ether extraction under the item of [discriminating] (2), add ethanol 30ml, heating and refluxing extraction 30 minutes filters, the filtrate evaporate to dryness, residue adds water 20ml makes dissolving, divides 2 extractions with water saturated n-butyl alcohol 30ml, merges n-butanol extracting liquid, wash with low amounts of water, discard water liquid, n-butyl alcohol liquid is put and is concentrated into about 1ml in the water-bath, adds an amount of aluminium oxide and mix drying thoroughly in water-bath, aluminium oxide pillar (200 orders that fill in advance of packing into, 1g, internal diameter 15mm) top, with methanol 30ml eluting, collect eluent, evaporate to dryness, residue add ethanol 1ml makes dissolving, as need testing solution.Other gets the peoniflorin reference substance, adds ethanol and makes the solution that every 1ml contains 2mg, in contrast product solution.Test according to thin layer chromatography (appendix VIB of Chinese Pharmacopoeia version in 2000), draw each 5 μ l of above-mentioned two kinds of solution, put respectively on same silica gel g thin-layer plate, with chloroform-ethyl acetate-methanol-formic acid (40: 5: 10: 0.2) be developing solvent, launch, take out, dry, spray is with 5% vanillin sulfuric acid solution, and it is clear that hot blast blows to the speckle colour developing.In the test sample chromatograph, with the corresponding position of reference substance chromatograph on, show the speckle of same color.
Claims (4)
1. a medicine for the treatment of gynaecopathia is characterized in that being made up of following Chinese medicine and percentage by weight: Radix Angelicae Sinensis 6-12, Radix Rehmanniae Preparata 6-12, Radix Dipsaci 6-12, Radix Paeoniae Alba 6-12, Rhizoma Dioscoreae 6-12, Rhizoma Atractylodis Macrocephalae 6-12, Radix Sanguisorbae 6-12, Radix Angelicae Dahuricae 6-12, Concha Ostreae 6-12, Endoconcha Sepiae 6-12, Colla Corii Asini 6-12, Crinis Carbonisatus 4-7.
2. a kind of medicine for the treatment of gynaecopathia according to claim 1 is characterized in that preferred proportioning is: Radix Angelicae Sinensis 7.5-9.5, Radix Rehmanniae Preparata 7.5-9.5, Radix Dipsaci 7.5-9.5, Radix Paeoniae Alba 7.5-9.5, Rhizoma Dioscoreae 7.5-9.5, Rhizoma Atractylodis Macrocephalae 7.5-9.5, Radix Sanguisorbae 7.5-9.5, Radix Angelicae Dahuricae 7.5-9.5, Concha Ostreae 7.5-9.5, Endoconcha Sepiae 7.5-9.5, Colla Corii Asini 7.5-9.5, Crinis Carbonisatus 5.0-6.5.
3.., it is characterized in that said medicine is a tablet according to claim 1,2, described a kind of medicine for the treatment of gynaecopathia.
4. the preparation method of the Chinese medicinal tablet of treatment gynaecopathia according to claim 4, its feature may further comprise the steps:
(1) Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Rhizoma Dioscoreae half and half amount and Crinis carbonisatus powder are broken into fine powder, sieving for standby;
(2) Radix Angelicae Sinensis, Radix Angelicae Dahuricae pulverize separately become coarse powder, and wherein Radix Angelicae Sinensis is made solvent with 5～6 times of amount 70% ethanol, and the Radix Angelicae Dahuricae is made solvent with 5～6 times of amount 60% ethanol, and percolation carries out percolation, collects the liquid of filtering, makes extractum routinely respectively
(3) five tastes such as all the other Radix Rehmanniae Preparata and the remaining Radix Paeoniae Alba, the Rhizoma Atractylodis Macrocephalae, Rhizoma Dioscoreae decoct with water secondary, and 3 hours for the first time, 2 hours for the second time, collecting decoction filtered, and filtrate is concentrated into relative density and is about 1.28 thick paste;
(4) after the adding Colla Corii Asini dissolves, add above-mentioned powder again, mixing, drying is ground into fine powder; Add Radix Angelicae Sinensis, Radix Angelicae Dahuricae extractum, mixing is granulated, and compacting is in blocks, and sugar coating promptly.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021398054A CN1219532C (en) | 2002-12-06 | 2002-12-06 | Chinese herbal medicine for treating gynecology disease and its preparing method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB021398054A CN1219532C (en) | 2002-12-06 | 2002-12-06 | Chinese herbal medicine for treating gynecology disease and its preparing method |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1480173A true CN1480173A (en) | 2004-03-10 |
| CN1219532C CN1219532C (en) | 2005-09-21 |
Family
ID=34147507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB021398054A Expired - Fee Related CN1219532C (en) | 2002-12-06 | 2002-12-06 | Chinese herbal medicine for treating gynecology disease and its preparing method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1219532C (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101856431A (en) * | 2010-06-02 | 2010-10-13 | 南京中医药大学 | Medicament for treating liver-kidney yin deficiency type anovulatory dysfunctional uterine bleeding, and preparation method and application thereof |
| CN102100843A (en) * | 2011-03-11 | 2011-06-22 | 杨萍萍 | Chinese medicine composition for treating virgin metrorrhagia and metrostaxis and using method thereof |
| CN101502634B (en) * | 2009-03-06 | 2011-11-02 | 陈殿红 | Chinese medicinal composition for treating uterine blood flow and preparation method thereof |
| CN101119740B (en) * | 2004-12-14 | 2012-02-29 | 成都地奥制药集团有限公司 | Use of radix sanguisorbae and its extract for preparing medicament to increase RBC and hemoglobin |
| CN105434775A (en) * | 2015-12-07 | 2016-03-30 | 黄卫忠 | Chinese patent medicine treating leukorrheal diseases and preparation method thereof |
| CN106214910A (en) * | 2016-08-22 | 2016-12-14 | 湖南康尔佳制药股份有限公司 | A kind of medicine treating dysfunctional uterine bleeding and preparation method thereof |
| CN106418528A (en) * | 2016-12-27 | 2017-02-22 | 山东鲁健生物医药科技有限公司 | Health food for functional uterine bleeding patients and preparation method of health food |
-
2002
- 2002-12-06 CN CNB021398054A patent/CN1219532C/en not_active Expired - Fee Related
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101119740B (en) * | 2004-12-14 | 2012-02-29 | 成都地奥制药集团有限公司 | Use of radix sanguisorbae and its extract for preparing medicament to increase RBC and hemoglobin |
| CN101502634B (en) * | 2009-03-06 | 2011-11-02 | 陈殿红 | Chinese medicinal composition for treating uterine blood flow and preparation method thereof |
| CN101856431A (en) * | 2010-06-02 | 2010-10-13 | 南京中医药大学 | Medicament for treating liver-kidney yin deficiency type anovulatory dysfunctional uterine bleeding, and preparation method and application thereof |
| CN101856431B (en) * | 2010-06-02 | 2011-08-31 | 南京中医药大学 | Medicament for treating liver-kidney yin deficiency type anovulatory dysfunctional uterine bleeding, and preparation method and application thereof |
| CN102100843A (en) * | 2011-03-11 | 2011-06-22 | 杨萍萍 | Chinese medicine composition for treating virgin metrorrhagia and metrostaxis and using method thereof |
| CN105434775A (en) * | 2015-12-07 | 2016-03-30 | 黄卫忠 | Chinese patent medicine treating leukorrheal diseases and preparation method thereof |
| CN106214910A (en) * | 2016-08-22 | 2016-12-14 | 湖南康尔佳制药股份有限公司 | A kind of medicine treating dysfunctional uterine bleeding and preparation method thereof |
| CN106418528A (en) * | 2016-12-27 | 2017-02-22 | 山东鲁健生物医药科技有限公司 | Health food for functional uterine bleeding patients and preparation method of health food |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1219532C (en) | 2005-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101837065B (en) | Medicine with anti-hepatitis, anti-tumour and organism immunity improving functions and preparation method thereof | |
| CN1739714A (en) | Chinese medicine prepn of invigorating kidney and benefiting vital energy and its prepn process and quality control method | |
| CN1219532C (en) | Chinese herbal medicine for treating gynecology disease and its preparing method | |
| CN100341547C (en) | Medicinal composition for regulating blood fat, prepn. method and use thereof | |
| CN1887324B (en) | Chinese medicine composition for treating liver and kidney defect, and its preparation process and analysis method | |
| CN1876051A (en) | Chinese medicinal preparation for treating gynecological disease, its preparation process and quality control method | |
| CN1891284A (en) | Chinese medicine composition, and its preparing method and quality control method | |
| CN101940642A (en) | Chinese medicinal composition and application thereof | |
| CN102151318B (en) | Traditional Chinese medicinal composition for treating gynecopathy, and preparation method and detection method thereof | |
| CN101129974A (en) | Traditional Chinese medicine composition for treating hepatopathy and method of preparing the same | |
| CN1272027C (en) | Desmodium preparation for treating urinary calculus, infection and cholelithiasis cholecy stolithiasis and chole cystitis and its production method | |
| CN111643594B (en) | Traditional Chinese medicine composition for treating opioid-related constipation, preparation method and application thereof | |
| CN102976943A (en) | Alpha-crystal form substance of danshinolic acid A, preparation method, pharmaceutical composition and application | |
| CN1712060A (en) | Preparation of Chinese medicinal mixture for treating gynecologic menstrual disease | |
| CN1887328A (en) | Chinese medicine composition and its prepn process and quality control method | |
| CN100479837C (en) | Weinakang for treating ischemic cerebrovascular disease and senile dementia and preparation method thereof | |
| CN101011543B (en) | Antineoplastic medicine composition | |
| CN1285377C (en) | Gynecological inflammation treating medicine and its preparation method | |
| CN1548066A (en) | Dysmenorrhea treating solid medicine prepn and its prepn process | |
| CN100434092C (en) | Prescription containing sweet clover component and its formulation | |
| CN1241586C (en) | Chinese medicine composition and preparing method thereof | |
| CN1879839A (en) | Mongolian medicine Baolier for treating hyperlipemia and method for preparing same | |
| CN1833701A (en) | Ten-element capsule for treatment of dept. of gynecology and prepn. thereof | |
| CN115814041B (en) | A Chinese medicinal composition for treating headache, and its preparation method | |
| CN1238028C (en) | Method for preparing capsule of six drugs containing rehmannine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: CHANGSHA KANGERJIA PHARMACY GROUP CO.,LTD. Free format text: FORMER OWNER: CHANGSHA TAIBAO PHARMACEUTICAL CO., LTD. Effective date: 20100121 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20100121 Address after: No. 198, west slope, Tongzi, Hunan, Changsha: 410205 Patentee after: Changsha kaang'er Pharmaceutical Group Co., Ltd. Address before: No. 17 South Shaoshan Road, Hunan, Changsha Patentee before: Taibao Pharmaceutical Co., Ltd., Changsha |
|
| ASS | Succession or assignment of patent right |
Owner name: HU'NAN KANGERJIA PHARMACEUTICAL MANAGEMENT GROUP C Free format text: FORMER OWNER: CHANGSHA KANGERJIA PHARMACEUTICAL GROUP CO., LTD. Effective date: 20101119 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20101119 Address after: 410205 No. 198 west slope road, Changsha, Hunan, Tongzi Patentee after: Hunan Kang Medicine Management Group Co., Ltd. Address before: 410205 No. 198 west slope road, Changsha, Hunan, Tongzi Patentee before: Changsha kaang'er Pharmaceutical Group Co., Ltd. |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Hunan Kang Medicine Management Group Co., Ltd. Document name: Notification to Pay the Fees |
|
| DD01 | Delivery of document by public notice | ||
| DD01 | Delivery of document by public notice |
Addressee: Hunan Kang Medicine Management Group Co., Ltd. Document name: Notification of Termination of Patent Right |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050921 Termination date: 20181206 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |